Gradient Investments LLC Buys Shares of 55,473 Insulet Corporation $PODD

Key Points

• Gradient Investments LLC acquired a new stake in Insulet Corporation, purchasing **55,473 shares** valued at approximately **$17.4 million** during the second quarter.
• Insulet Corporation reported EPS of **$1.17** for the last quarter, exceeding analysts' expectations of **$0.92**, and saw a significant **32.9% increase** in revenue year-over-year.
• Despite recent insider selling, **analysts have upgraded** Insulet's stock rating, with a consensus of **16 "buy" ratings** and a revised target price around **$335.12**.

Gradient Investments LLC bought a new stake in Insulet Corporation (NASDAQ:PODD - Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 55,473 shares of the medical instruments supplier's stock, valued at approximately $17,429,000. Gradient Investments LLC owned about 0.08% of Insulet as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC lifted its stake in Insulet by 55.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier's stock valued at $1,376,000 after buying an additional 1,867 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Insulet by 2.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,909 shares of the medical instruments supplier's stock valued at $5,228,000 after purchasing an additional 440 shares in the last quarter. Farther Finance Advisors LLC raised its stake in shares of Insulet by 85.1% during the first quarter. Farther Finance Advisors LLC now owns 896 shares of the medical instruments supplier's stock valued at $236,000 after purchasing an additional 412 shares in the last quarter. QRG Capital Management Inc. raised its stake in shares of Insulet by 75.6% during the first quarter. QRG Capital Management Inc. now owns 2,030 shares of the medical instruments supplier's stock valued at $533,000 after purchasing an additional 874 shares in the last quarter. Finally, Exchange Traded Concepts LLC raised its stake in shares of Insulet by 225.4% during the first quarter. Exchange Traded Concepts LLC now owns 1,552 shares of the medical instruments supplier's stock valued at $408,000 after purchasing an additional 1,075 shares in the last quarter.

Insulet Trading Up 1.1%

Shares of PODD opened at $341.78 on Monday. The business's 50-day moving average price is $311.59 and its 200 day moving average price is $292.31. The stock has a market capitalization of $24.06 billion, a P/E ratio of 103.88, a P/E/G ratio of 2.84 and a beta of 1.36. Insulet Corporation has a 1-year low of $225.37 and a 1-year high of $353.50. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping analysts' consensus estimates of $0.92 by $0.25. The firm had revenue of $649.10 million for the quarter, compared to analysts' expectations of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.Insulet's revenue was up 32.9% on a year-over-year basis. During the same quarter last year, the business posted $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Analysts expect that Insulet Corporation will post 3.92 earnings per share for the current year.

Insider Transactions at Insulet

In other Insulet news, SVP Prem Singh sold 687 shares of Insulet stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares of the company's stock, valued at $1,200,925.44. The trade was a 16.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.39% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on PODD shares. Wall Street Zen upgraded shares of Insulet from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. The Goldman Sachs Group began coverage on shares of Insulet in a research note on Friday, May 30th. They set a "buy" rating and a $380.00 price objective on the stock. Canaccord Genuity Group lifted their target price on Insulet from $331.00 to $353.00 and gave the stock a "buy" rating in a report on Friday, August 8th. Citigroup reissued a "buy" rating on shares of Insulet in a report on Tuesday, July 8th. Finally, Raymond James Financial restated an "outperform" rating and set a $360.00 price objective (up previously from $328.00) on shares of Insulet in a research report on Tuesday, May 27th. Sixteen research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $335.12.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.